Who Paid My Doc
Jason Morris
Family Medicine Lake Charles, LA Medical Doctor
NPI 1861468068 CMS profile 266086
277 Highway 171, Suite 8, Lake Charles, LA 70611
General payments
$7,281
Research payments
$1,090,809
Ownership & investment interest
$0
Research they led as principal investigator
$17,966,286
Through program year 2025, Jason Morris of Lake Charles, LA is reported in the CMS Open Payments database as having received $7,281 across 418 general payments and $1,090,809 in research payments paid to them. Separately, studies naming them as principal investigator received $17,966,286 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $636 | 26 | |
| 2024 | General | $756 | 33 | |
| 2024 | Research | $126,434 | 2 | |
| 2023 | General | $1,163 | 66 | |
| 2023 | Research | $21,075 | 4 | |
| 2022 | General | $1,596 | 100 | |
| 2022 | Research | $103,582 | 1 | |
| 2021 | General | $1,331 | 83 | |
| 2021 | Research | $167,301 | 2 | |
| 2020 | General | $867 | 49 | |
| 2020 | Research | $672,417 | 2 | |
| 2019 | General | $932 | 61 |
Beside peers
- Jason Morris
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Jason Morris were reported at $636. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Jason Morris | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $932 | $150 | $41–$543 | $163 |
| 2020 | $867 | $120 | $32–$415 | $114 |
| 2021 | $1,331 | $137 | $35–$551 | $132 |
| 2022 | $1,596 | $137 | $37–$512 | $149 |
| 2023 | $1,163 | $149 | $42–$545 | $160 |
| 2024 | $756 | $156 | $44–$560 | $164 |
| 2025 | $636 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 157 drugsPart D claims
8,825
Drug cost
$818,907
Branded share of claims
21.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 143 | $139,417 | |
| Mounjaro Tirzepatide | Brand | 94 | $116,023 | |
| Farxiga Dapagliflozin Propanediol | Brand | 85 | $65,322 | |
| Januvia Sitagliptin Phosphate | Brand | 67 | $52,376 | |
| Trulicity Dulaglutide | Brand | 34 | $44,887 | |
| Eliquis Apixaban | Brand | 61 | $41,174 | |
| Rexulti Brexpiprazole | Brand | 26 | $37,154 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 30 | $28,041 | |
| Jardiance Empagliflozin | Brand | 31 | $25,462 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 29 | $23,740 |
The 10 drugs with the highest cost, of 157 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 131 billing codesPaid by Medicare
$355,639
Medicare patients
960
Services billed
15,375
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Ischemic heart disease | 35% | |
| Diabetes | 28% | |
| Depression | 25% | |
| Chronic kidney disease | 22% | |
| COPD | 17% | |
| Atrial fibrillation | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 262 | 1,235 | $5,971 |
| Influenza vaccine, trivalent derived from recombinant dna 90673 | Office | 34 | 34 | $2,782 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 262 | 1,243 | $376 |
| Vaccine for tetanus and diphtheria toxoids injection into muscle, patient 7 years or older 90714 | Office | 11 | 11 | $287 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 82 | 362 | $178 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 99 | 1,026 | $75 |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram J7644 | Office | 13 | 13 | $3 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg J7611 | Office | 18 | 18 | $2 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 | Office | 13 | 13 | $2 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 21 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| FARXIGA |
|
$135 | 85 | — |
| UBRELVY |
|
$68 | — | — |
| AIRSUPRA |
|
$66 | — | — |
| BREZTRI |
|
$52 | — | — |
| QULIPTA |
|
$26 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 21 in the dashboard with a free accountRecords
429 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Louisiana
Related records
Family Medicine in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.